CORCYM
1.6.2021 11:49:14 CEST | Business Wire | Press release
CORCYM
the new, independent, medical device company dedicated to providing patients and heart surgeons with the best solutions to fight structural heart disease, announces today the launch of operations globally.
Born from the acquisition of the LivaNova PLC (LivaNova) heart valve business by Gyrus Capital (Gyrus), an investment firm dedicated to investments in the healthcare and sustainability sectors, CORCYM enters the market with a comprehensive portfolio of products to fit the needs of heart surgeons and patients worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005463/en/
“We are glad to announce the global launch of CORCYM” said Christian Mazzi, CORCYM CEO . “We enter the market today with the strong legacy and heritage of a product portfolio that spans over 50 years. We are committed to becoming the leading company dedicated to heart surgeons and their patients “.
From the Latin COR (heart) and CYM (valve, shortened from Cymbalon) the company name defines its focus: to provide heart surgeons with the best solutions to fight structural heart disease. CORCYM has a presence in over 100 Countries and counts on two main production sites, in Saluggia, Italy, and Burnaby, Canada. With approximately 850 employees globally, the company ensures a strong presence to continuously support patients, healthcare professionals and healthcare systems worldwide.
“Our mission is to help heart surgeons treat patients better today and in the future. Our plan is to leverage our foundations in mechanical valves and build our growth engine with our leading product platforms Perceval® and Memo, while investing in research and development to pursue new products and partnerships. We intend to build CORCYM as a focused, customer-centric and agile company, backed by Gyrus, a strong sector-focused partner that is ready to invest in our future. ” said CEO Mazzi.
Clinical evidence will play a vital role in the future of CORCYM heart valve technologies. CORCYM will support a vibrant clinical program in collaboration with leading professionals in heart surgery, to develop clinical studies and investigator-initiated research activities. CORCYM is also committed to continuing and expanding its robust educational and training programs for all its heart valve solutions.
Legal Note
As of today, LivaNova and CORCYM completed the initial closing relating to CORCYM’s acquisition of the LivaNova heart valve business. In the initial closing, CORCYM acquired LivaNova manufacturing facilities in Saluggia and Burnaby (Vancouver) and related assets in other geographies, representing most of the heart valve business. During the course of 2021, the parties expect to complete the transfer of the commercial operations in various local jurisdictions.
About CORCYM
CORCYM is a global, independent, medical device company entirely focused on state-of-the-art surgical solutions to fight structural heart disease. CORCYM has a presence in more than 100 countries with approximately 850 employees and ensures strong continuous support to patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.corcym.com
About Gyrus Capital
Gyrus Capital is an investment firm focused on transformational investments in the healthcare and sustainability sectors. Based in Geneva, Switzerland, the firm specializes in $50-500m carve outs of businesses with great product and people, which are non-core to their parent corporates. The LivaNova HV carve out follows the acquisition of DuPont Sustainable Solutions (global leader in occupational health and risk and safety consulting) from E.I. DuPont de Nemours in 2019. To learn more, visit www.gyruscapital.com .
About LivaNova
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210601005463/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 14:00:00 CET | Press release
The combination connects AI-driven financial and operational planning, analytics and execution across Microsoft Excel and Power BI, removing decision latency for Microsoft-centric enterprises. Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap wid
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 14:00:00 CET | Press release
• 45% of C-level executives plan to establish a U.S. legal entity within the next 12 months; a further 27% say they will consider entry within two to three years • 65% cite supply chain or manufacturing efficiency as the primary driver for U.S. expansion • 88% identify federal and state tax reporting as the most burdensome area of U.S. compliance Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expa
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release
COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom